This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: Good afternoon and welcome to the CBIS third quarter 2023 results conference call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. At that time, if you have a question, please press the 1 followed by the 4 on your telephone keypad. If at any time during the conference you need to reach an operator, please press star 0. Please also note, today's event is being recorded. At this time, I'd like to turn the conference over to Wade King, Chief Financial Officer. Sir, please go ahead.
spk01: Thank you, and good afternoon. This is Wade King, the Chief Financial Officer of CBIS. I would like to thank you for taking time to join us for CBIS Third Quarter 2023 Financial Results and Corporate Update Conference Call and Webcast. Beginning with me today is Rory Riggs, our Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer. Before we begin the conference call, I'd like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects, are forward-looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call. please refer to SEVIS SEC filings for a list of associated risks. This conference call is being webcast. The webcast link, along with our press release and corporate presentation, are available on the investor relations section of SEVIS.com to assist in your analysis of the business. With that, I would now like to turn the call over to Mr. Riggs. Go ahead, Rory.
spk05: Thanks, Wade. And welcome to everybody on the call. I'll begin by highlighting several of our recent business and commercial updates. Then Peter and I will walk you through where we are and where we are headed. Lastly, Wade will finish with a brief discussion of the financials. The goal of this format is to provide you with an educational overview of our business, its pipeline, and their prospects so that you're better equipped with a solid foundation to better understand our company, and to track our events and progress. With that, I'd like to discuss some of our recent business and commercial updates. Since going public in June of this year, we have been laser focused on driving our evolution from an R&D company to a commercial company. As part of this transition, we underwent a strategic alignment in October aimed at bringing enhanced focus to our primary commercial goal, which is furthering the advancement of our commercial activities. All of our resources and operations are now centered on completing the launch of our initial traits. Importantly, our three developed traits, pod shatter reduction, often referred to as PSR in canola, and in rice, HT1, herbicide tolerance number one, and HT3, herbicide tolerance number three, as well as the advancement of our soybean platform, and bolstering the development of our advanced traits, square of senior resistance and HT2 in both canola and soybean. Notably, our realigned efforts have captured this focus and priorities. I'll speak to our progress in each of these traits a little later on. Concurrent with our strategic realignment, we have also implemented some necessary cost reduction measures. with the objectives of preserving capital resources for the advancement of these five traits. We believe that refocusing on our strengths and top priorities will position us well to achieve our strategic objectives in a more timely manner. We're working hard to make sure that happens. So let me take you to our five traits three crop business model. Although royalties haven't started yet, Our commercialization efforts are well underway. They are centered around advancing five traits with applications in three major crops, rice, canola, and soybean. Combined, we believe this represents an addressable market opportunity of over 250 million acres and over $1 billion in potential royalties across canola, rice, and soybeans. We believe that this five-trade, three-crop model is just the beginning of what our capabilities can ultimately address. One of our key accomplishments of our scientists has been their mastery of oligonucleotide-directed mutagenesis, our single-cell editing technology, and our production system supporting each crop platform. For many, The even bigger accomplishment is the fact that with this technology platform, the team at SEVIS has been able to generate a product pipeline of five important traits. Three of these traits are fully developed, have multiple years of successful field trials, and strong intellectual property. Important for each trait, we now have a strong customer base. In addition, SEVIS has built two crop platforms at canola and waste, as well as being close to a third crop platform in soybeans. Our soybean platform has been under active development for several years, and we expect to have the soybean platform operational in Q4 2023. Now that we have these three traits developed and we've been commercializing them through a high-throughput editing process, accelerating our development timeline, we are very excited about the prospects for these three traits. In this process, we edit our customers' proprietary germplasm and then transfer their germplasm back to them with our traits. we can now execute this process very quickly, allowing the customer to accelerate their commercialization process. Once satisfied and the results are confirmed, then the customer develops a registration dossier, initiates its marketing plan, bulks up its seed inventory, and ultimately distributes the seed to farmers, at which point the royalties begin being paid to see this. We consider our first trade product to be our pod shatter-resistant trade, PSR. It's strengthened the sheath around the canola seeds, which protects the crops in extreme weather conditions. We have shown PSR's efficacy in multiple field trials. Based on these field trials, we now have 10 different customers that we estimate represent over 20 million acres of canola WOSR. We now have edited these crops and have started returning to customers that are leaf germplasm with our PSR trait. As we have stated, we expect to complete transfers to six customers in 2023. Additionally, we expect in 2024 to transfer the remaining customers and increase our market penetration with additional customers. We estimate that the annual trade royalty from PSR could be approximately $200 million annually. In addition to PSR, the two developed trades are HD1, HD3, and RICE. They are important genetic traits for herbicide tolerance or weed management. Over 95% of canola, soybean, and corn currently utilize GMO-based herbicide traits for weed management. Rice has never had GMO traits. This is why these two traits are in high demand in rice. We have already transferred our first HD1, HD3 traits in rice to Nutrin for the North American market. We now have three customers who we believe represent over 4 million acres in North and South America. We expect additional customers in North America and South America in 2024. We estimate that the annual trade world sheet for use for HD1, HD3, and rice could be approximately $150 million a year. These HD traits are now fully developed and validated, and similar to our work in PSR, we'll be tracking the progression to customers' commercial lines that will generate our future royalty streams. The progression of these three traits has accelerated significantly in 2023. We are shipping edited traits back to customers and are also adding new customers across both canola and soybean. We look forward to updating you on the progress of these three traits in these two crops over the preceding quarters. In addition to our developed traits, our two advanced traits are critically important. They're both multi-crop traits, meaning they have potential efficacy across multiple crop types. The first advanced trait is HT2, or herbicide resistance number two, for weed management. Because of the extensive overuse of certain modes of action over the last 20 years, many weeds have become resistant to those herbicides. For crops like canola and soybean, there is extensive demand for new broad-spectrum herbicides and associated herbicide traits that target broad-leaf weeds. That is the market for HD2. We expect important greenhouse results next summer for this trait. Because of its demand in both canola and soybean, we believe it has the potential to be the first GMO-based trait to exceed 100 million acres. From perspective, the industry estimates that GMO-based herbicide traits are utilized currently on over 300 million planted acres. The second advanced trait is for sclerotinia, or white mold resistance. Sclerotinia is the most damaging disease in canola and one of the major diseases impacting soybean. As a disease trait, this is not a single mode of action trait. In order to be durable, this trait needs to address multiple parts of disease conditions. If successful, this would be the first major disease trait that would be applicable to multiple crops. If this trait is successful and deployed across both canola and soybean, we believe that this trait has the potential to be the largest gene-edited trait to date. The development of these two traits have progressed well in 2023. Over the next years, we will track the progression of these two traits also and their advancement to customers' commercial lines and to their royalty payouts. These traits and their royalty fans will be a significant component of our economic base and profitability. We will follow this progress on a quarterly basis very closely. Soybean is the last component of our five-trade, three-crop business plan. We have had significant progress in completing our soybean single-cell editing platform. As we have stated, we still believe that we will complete development of this platform in FY2023. Over the next few years, we will track the progression of our soybean business. Once we have achieved our platform, we expect significant growth in soybean customers based on initial discussions we have had to date. This is a large 200 million plus acre crop in just North and South America. Many of the major soybean seed companies are already customers of Seabus and other crops. We believe that soybeans will be a major contributor contributor of our economic space going forward and a central pillar of the growth of gene editing in agriculture. As is clear, our five-trade, three-crop model is the central focus of our corporate strategy. We intend to track the progression of each trait as it is deployed in the elite germplasm, and the progression of each will be central to our quarterly updates going forward as each trait by crop combination starts generating royalty revenue. With that, I'd like to pass the call over to Peter for his remarks.
spk04: Thank you, Rory, and good afternoon to everybody. As Rory just mentioned, SEVIS's five-trait, three-crops model is at the forefront of agriculture's analog to digital moment. We say that because with these gene-edited traits, we are fundamentally changing the scale and speed of trait development in crops. The technology behind our rapid trait development system, RTDS, allows us to edit a single cell extracted from plants that represent the best plant genetics in the industry. We term this as a leaked germplasm. The edited cells from that elite germplasm are then regenerated into an identical elite germplasm with the targeted edits. This really is the key point of differentiation at CBIS from other gene editing technologies. With it, we have significantly reduced the time and expense of bringing new trait innovations to seed companies. Our focus continues to be scaling and acceleration of customers' gene-edited elite genetics. Here's how high-throughput gene editing, a.k.a. our trait machine, works. Once we secure approval from the seed company to edit their germplasm and we physically receive the germplasm from them, the developing of a product begins as it enters the trait machine. As we shared last quarter, we opened the first high-throughput semi-automated gene editing facility. And as Rory mentioned, we are excited to see our first customers enter the germplasm transfers in 2023. And this new facility is set to deliver additional products at scale and acceleration over the next 24 months. It's important to note that when we add a new trait to our portfolio, we don't have to invest in an entirely new machine. Instead, we simply use a new set of editing reagents. When we add a new crop to the platform, we just add in plug-and-play automation solutions while applying years of plant tissue culture experience to facilitate any changes that may be required. The relative simplicity of our design and the efficiency that it allows is the basis for our rapid development. while also helping curtail significant capex investments as we scale and accelerate our business. When we receive our customer's elite germplasm, it is processed and run through our trait machine. Once the molecular confirmation of the edit is complete, we validate the quality of that edit, the efficiency of the trace, and ensure the elite line is identical to what we initially received with the sole exception of the edits we made. This quality assurance is absolutely critical for our customers. We then proceed to generate a small supply of seeds to hand back to the customer so they can begin their commercialization process. We envision this entire process lasting between 18 to 24 months. It is important to note that at SEVIS, our early work on our developed traits has been completed in growth rooms, greenhouses, and field trialing over many years to showcase the process prior to entering the high-throughput editing process with customers to net. This early work we have completed provides excellent guidance for our customers on how we can accelerate their commercial process. Cutting down what has historically been a decades-long process to a few years is truly revolutionary and underpins our strategy to build a scaled, high-margin, high-free cash-flowing business. Back to you, Roy. Thank you.
spk05: Thanks, Peter. In summary, our commercialization efforts are well underway and are centered around advancing five trades with applications in three major crops. rice, canola, and soybean. Combined, we believe this represents an addressable market opportunity of over $1 billion in oil use, and our three-crop, five-trade model is just the beginning of what our capabilities can ultimately address. In addition to the five-trade, three-crop commercialization process, there are other elements that are also important to our commercialization efforts. The summer in agriculture is a key time for field studies, and this year we had an extensive field trial schedule for each of our traits. We also worked with our customers in the fields as we worked together to launch our three developed traits. Additionally, in the third quarter, we established our first multi-locational field network for sclerotinia white mold resistant testing of various modes of actions, that are progressing through our pipeline. This field performance network is critical to advance and demonstrate the efficacy of existing and additional modes of action for sclerotinia resistance. 2023 has also been a key year in the development of a new global regulatory regime for gene editing technology, specifically gene editing technology that does not use transgene. In recent years, we have seen the introduction of policy enabling the use of gene editing without the use of transgene in multiple countries around the world. Most recently, on July 5th, the EU College of Commissioners adopted the European Commission proposal on the regulation of plants obtained from new genomic techniques, often referred to as NGTs. The proposed regulation identifies a conventional white category of NGT products that would be regulated as conventional varieties, bringing EU closer to that of trading partners in North and South America, Australia, and Japan. In the proposal, the Commission highlights the potential of NGTs to contribute to a more sustainable agriculture, climate resilience, and food security. Under this proposal, products from SEBAS's gene editing platform would be considered conventional-like. The EU is important for many reasons. First, it is a critical bellwether for the rest of the world. Second, it represents over 100 million acres that have not had access to GMO trade technologies. And third, there are approximately 20 million acres of winter oil seed rate grown in Europe, which ties directly into our own strategy. Our PSR trade has been developed for this market, and we began field trials for this trade in the UK in 2023. The market is also suitable for our other advanced traits within our canola pipeline. These are major steps in the progression of our products and technology on a global basis. We will continue to monitor and update the progress on these regulatory advances as they occur, but we're on target for gene editing technology to be a globally approved methodology for advancing plant traits. Now I'll pass the call on to Wade to briefly review our financials.
spk01: Thank you, Rory. Looking at our financials for the third quarter, cash and cash equivalents was $31.9 million as of September 30th, 2023. We believe our cash and cash equivalents will enable us to fund planned operating expenses and capital expenditure requirements into the first quarter of 2024. R&D expense was $17.5 million for the third quarter of 2023, compared to $3 million in the year-ago period. The increase was primarily related to increased lab supply and facility expenses, an increase in employee headcount, and an increase in stock-based compensation expense for restricted stock awards. SG&A expense was $8.8 million for the third quarter of 2023, compared to $3.2 million in the year-ago period. The increase was primarily related to an increase in headcount, increased consulting and legal fees, and an increase in stock-based compensation expense for restricted stock grants. Non-operating expense was $0.9 million for the third quarter of 2023 compared to non-operating income of $0.3 million in the year-ago period. The decrease was due to changes in the fair value of the liability classified Class A common stock warrants. Net loss was $34.5 million for the third quarter of 2023 compared to a net loss of $6 million in the year-ago period. For additional details about our financials for third quarter of 2023, please refer to our press release and filings with the SEC. That concludes our financial discussion. Rory, back to you for your closing remarks.
spk05: Rory Madden Thanks, Wade, and many thanks to everyone for listening in. I can't tell you how excited we are to see what the future brings for CBIS. We believe that we are at a historic inflection point where we can, for the first time, bring rapid innovation to an industry that is hungry to solve the world's food shortages. With tailwinds from an improved regulatory environment and breakthroughs in trade development, our experienced team at CBIS is executing on the opportunities ahead of us as we continue to advance deployment of our traits to our customers' elite germplasm, to enhance their product offerings for the benefit of their farmer customer. We really look forward to updating you on the next call. Operator, that concludes our prepared remarks. You may now open up the call for Q&A.
spk07: Thank you. If you would like to register a question, please press the 1 followed by the 4 on your telephone. You will hear a three-tone prompt to acknowledge your request. And if your question has been answered and you would like to withdraw your registration, Please press the one followed by the three. And our first question is from the line of Bobby Burleson from Canaccord. Please go ahead.
spk03: Thank you. Hi, Rory and team. So I guess my first question is just around helping us understand how to prioritize some of the resources efforts currently underway. So, you know, if we can just look at some of the commercialization progress that you guys announced that took place over the quarter, maybe help us rank that in terms of significance by, you know, total addressable market opportunity or timeline or both.
spk05: Thanks, Bobby. That's a great question. We have these five traits. you totally realize they're prioritized. And our prioritize is really these three developed traits. And so the emphasis here is saying, what happened in the last quarter to get rice further along? And what happened in the last quarter to get pod chatter further along? And I'll let Peter talk to some of it. But because of the work we've done in rice, we now have really big debates in Latin America. We've already assigned one big customer, which we think represents plus or minus 1%. three and a half million acres, and we have a number of others right in the target. And so a real progress has been the development we've done in the commercial customers. And these are customers who are now in the process of sending us their germplasm and us putting our traits in their germplasm. And so our goal is over the next year to be able to take these germplasms and get it back to them with their traits so they can launch it. And the progress hopefully you'll follow is the contracts we're signing at acreage that go with it, and how fast we can turn around these germplasms. The goal in this business is to get these germplasms in people's crops so they can bulk up and loan. We're part of the launching process, so when we ship back, we'll have a pretty good sense of the time of when they bulk up and when they go. And on pod shatter, what's really interesting about pod shatter is, first, we have 10 traits. We've edited them, and we're in a different process of launching back. But I'd like Peter to talk about the big thing in pod shatter is, The ability we're now able to do with field studies and field studies with the customers and the combination of getting them their germplasm and their field studies, we have this model that all three of these traits are going to be ready for planting around the same time. But for each one of these things, we need to be really clear about the things we're doing to get them ready for that time and to be able to say whether things got delayed, but more importantly, tell you why we're encouraged by where they are and how to think about revenues. Peter, do you want to throw a little bit on plants and field studies?
spk04: I do. Thanks, Bobby, for the question, and thanks, Rory. I think the best way to think about our progress, and I'm going to specifically talk about canola pod shatter, is that, as Rory mentioned, we have 10 customers whose genetics, and I've mentioned it on the call, elite germplasms, in our hands and we're in the midst of transferring back to that. So, you know, so far in 2023, we've transferred two of our customer lines back. The whole group of elite genetics that we have in the hand equates to accessing, you know, as much as 20 million acres over time. So what's exciting for us is that that transfers are starting to occur and then the field trials that we're doing are with the canola hybrids with pod-shadow trait in them were very successful this last summer. We're so excited to see the traits in the field in customer genetics. And then this winter, we'll be looking at canola hybrids in winter nurseries and really move to that next level of pre-commercialization performance evaluation in 2024.
spk05: Thanks, Peter. And then, Bobby, the other thing, we're so focused on these three traits and two crops, we just can't ignore the fact that we're so excited about soybeans. And we're doing it in GDM germplasm, but we really are excited that we'll be able to finish that this year. And once we do that, it's really this big opportunity that suddenly, we believe once people think we have this single-cell model that regenerates back into a plant in soybean, that we have a lot of customers in the soybean business. there's just a really big opportunity to build this business. Does that address your question? Yeah, that's very helpful.
spk03: Yeah, that's great. And then just to follow up, obviously this EU draft on their proposed regulatory treatment of what I was calling NBTs, but I guess there are lots of acronyms, sounds very positive, right? And I'm wondering, can you kind of draw a parallel, you know, between what they're talking about doing and what Canada has already done? And then, you know, what, I guess, where is the demand coming from in the EU? Is this something that's been kind of in the works for a long time in order to change these regulations? You know, are they constrained in some ways food security wise or, re-evaluating how they're regulating other aspects of their food system and this is being pulled along with it.
spk05: Thanks. Peter, let me take the overview and let you go to the specifics for the customers. I think it would be helpful for them to understand the actual customers we have in canola and how broad our demand is from the customers in canola and the fact that we can now do studies in the UK. But the biggest shock we have, UK has been under a three-year process tried to change their laws so the gene editing that doesn't include transgenes gets treated as conventional breeding. And there's really big consensus across Europe. The productivity in Europe has so gone down, not having any GMOs at all, and so they need this law. And we, when they did their safety study, they basically said our technology was safe, and they drew it. But what surprised us was, This was probably three months before, when we said that in our press release, three months before we thought it would happen. And in the press release, they talked about taking it to Parliament in February, we're thinking of June. So we're pretty excited that there's really not just forward progression, but they're trying to speed up the process to get it behind us. But Peter, you might go, if that's helpful, it's really an encouraging moment for all of us. And the UK having passed it so we can now do field studies in the UK is a big deal because it allows us to start the progression of these products that are grown in Europe. Peter, you want to add to the customers?
spk04: Yeah, exactly, Rory. I think, Bobby, your question around this is really on point because it's clear that the EU is trying to accelerate this regulatory, which is which is not the normal state of affairs. And so a number of our customers are based in Europe and are very excited with the opportunity to bring traits to market. Now, the whole of Europe is a 100 million acre market that just hasn't had a lot of innovation in the last 30 years. To the point about improving sustainable agriculture, climate resilience and food security, they are big drivers for regulatory change. So these tailwinds to bring improved products onto the marketplace is really seen by our customers as a huge step. The fact is we have three of our customers' genetics and the trials in the UK over the winter into the spring of 2024. That is a first for canola, winter oilseed rape. And it's exciting to see that because I think that alignment globally, and you mentioned Canada in your question, is seeing a lot of progress on the regulatory front for harmonizing where the regulatory agencies are on, you know, in Europe they call them new genomic techniques, but essentially products from gene-edited technology and technology specifically ones like CBUS, where we have a non-transgenic process and a non-transgenic product. So they're harmonizing around the world, and that really opens up global markets for someone like CBUS. That's really helpful.
spk05: We have a couple of customers under contract already, and the neat thing is to think about this 100 million acres that's never had a weed trade, ever. We have three now, so it's a big opportunity for us. I'm sorry.
spk03: No, that's a great additional color, and to be clear, this also would cover imports into the EU.
spk05: Yes, the key to these laws are once you do that, it means when we develop a trait, it will be treated like conventional breeding coming into Europe. For people who aren't familiar with it, Europe treats GMO products almost like drugs, and it takes I think, three to five years to get approval. But suddenly everything we develop will have clear export approval. And I think that it's going to be a big moment for the industry. Boy, it'll be a big moment for soybeans to be able to introduce new traits that don't.
spk03: Yeah, understood. So, yeah, this could be huge. And maybe just looking at where there is GM technology, you know, you know, existing in germplasm, is there interest simply just because of the speed at which you can introduce a trait and at the lower cost where you'll potentially be stacked on some of these GM seeds, you know, as a significant part of what you're doing over time?
spk05: It totally is, but pod shatter, they don't have that trait. And that's not one that's all about speed. The fact of the matter is our team has actually developed real traits. So the first part is there's actually real traits. And then the speed thing is the fact that literally if you send us your germplasm in canola, now that Peter and Greg have figured out how to take a single cell from that germplasm, edit it, and grow it, that if you send us your germplasm in 18 to 24 months, we can have our trait in your germplasm. I'm ready to do field trials. Peter, you want to add to that?
spk03: It seems like that's an important distinction, right? Because people might be tempted to think this is purely gene-edited seeds, but the market's much bigger, right? Because we're talking about pretty much all seeds where your technology has relevance.
spk04: Yeah. Let me add in, Bobby, because I I think you hit on a really important point. For us who have been in tech for over 30 years, the recognition is that there was limitations to GMO, major limitations on what you could do. In my mind, it's like Windows 95. It's very old technology. Bringing forward gene-edited traits is just bringing forward traits that are really valuable in the market. There's markets where we can access where there's been a complete barrier to getting GMOs in, where you're free and clear with gene editing. And then there's going to be other markets, more global markets, perhaps in North and South America, where we'll be adding traits to genetics that already have traits. And so the expansion... an opportunity is huge. Plus the fact is that gene editing can address traits like serotinia, like white mold, disease resistance, where other technologies could not in the past. So not only does it open up global markets, it opens up opportunities of traits that were never able to be done using other technologies.
spk03: Well, thank you both. I'm going to let somebody else ask a question here because I realize it's the best four or five in a row.
spk05: Thank you. All good. Peter, all these breaking, can you tell us about India? India is such a big marketplace for both soybean and rice.
spk04: I think India has nearly 100 million acres of rice. It's a very fragmented market, but it has a huge appetite for trace. Just recently, by a that they are targeting 20% of that market, so 20 million acres around, which is what they call direct seeded market in India. That's just an example of where you can, you know, a trait like herbicide tolerance is something you really need to be able to do direct seeded rice. So there's an appetite not only for opening up the markets to better genetics, but also genetics with traits. So India is a classic example of an emerging market in agriculture that will take on traits in rice as well as canola. It's a little bit different in India than different genetics than what's in North America, but it is a very close relative.
spk05: Thanks, Peter. Next? I apologize.
spk07: And our next question is from the line of Lawrence Alexander with Jefferies. Please go ahead.
spk02: Hi, good evening. This is Kevin Estock on for Lawrence. Just one question to me. To what extent has the volatility in the ag market distracted customers from research partnerships or changed their timetable and their milestones for next year?
spk05: I'll leave it to Peter on the volatility of the markets. The good news is that we're really focused on traits that are already developed, right, and we're trying to sell to. So we're not trying to focus on new research agreements as much. We want to see where we can develop what we have go out there. And we haven't seen decrease but more increase because people see we actually have actual traits that they can buy. Peter, do you want to add to that?
spk04: No, I think the volatility is there for sure. I think, you know, where we – where traits play a role is in the seed industry for increasing farmers' productivity. And so the appetite for our traits, because it's increasing, we see demand from our customers of additional genetics that they would like to have traits in so that they can deliver better profits for farmers by increasing their productivity. So the volatility actually, in my mind, accelerates the demand and requirements for technologies like CBIS is delivering to the seed customers.
spk02: Got it. Okay. Thank you very much.
spk05: It is a distinction between strict yield stuff and specific trade stuff, right? Specific productivity aspects of a trade, which has been interesting, I think. But thanks so much. Thank you.
spk07: And Mr. Riggs, there are no further questions at this time. I will now turn the call back to you for closing remarks.
spk05: Thanks, team, and thanks for the questions. I think that our goal in these calls now is to help you understand the progression. We have actual traits, and because of that, every quarter, like this was the field study quarter, every quarter there will be aspects to be able to track how well we are towards Our goal of having this in the field being accessed by farmers. And so I think that the things we've really talked about are, one, besides mapping our progression, the two big things everybody's going to see is, can we do soybean and get it off? Because that's just a big value moment for us. And two, Europe seems to be accelerating. And so... as quick as we can get Europe behind us, suddenly we've become a real three crop, five trade business model, and we've become truly global. And we're really excited by it. And the most important part is just sort of understanding our progression and following it. If you guys have any more questions, please call. It's a really exciting moment for us to be able to track. Peter, you want to add anything?
spk04: I think that's a good summation, Roy. Definitely an inflection point for where we are.
spk05: Cool. Thanks, guys. Thanks, Tim. I think we're done.
spk07: That does conclude your conference call for today. We thank you for your participation and ask that you please disconnect your lines.
Disclaimer